Guidelines Of Care For The Management Of Basal Cell Carcinoma
5-year follow-up; aminolevulinate photodynamic; basal cell carcinoma; biopsy; curettage; Dermatology; expectancy; fresh tissue technique; hedgehog pathway inhibitor; imiquimod 5-percent cream; limited life; metastasis; mohs micrographic surgery; nonmelanoma; open-label trial; phototherapy; radiotherapy; randomized controlled trial; skin-cancer; staging; Surgery; surveillance; therapy; topical therapy
Basal cell carcinoma (BCC) is the most common form of human cancer, with a continually increasing annual incidence in the United States. When diagnosed early, the majority of BCCs are readily treated with office-based therapy, which is highly curative. In these evidence-based guidelines of care, we provide recommendations for the management of patients with BCC, as well as an in-depth review of the best available literature in support of these recommendations. We discuss biopsy techniques for a clinically suspicious lesion and offer recommendations for the histopathologic interpretation of BCC. In the absence of a formal staging system, the best available stratification based on risk for recurrence is reviewed. With regard to treatment, we provide recommendations on treatment modalities along a broad therapeutic spectrum, ranging from topical agents and superficially destructive modalities to surgical techniques and systemic therapy. Finally, we review the available literature and provide recommendations on prevention and the most appropriate follow-up for patients in whom BCC has been diagnosed.
Bichakjian C; Armstrong A; Baum C; Bordeaux J S; Brown M; Busam K J; Eisen D B; Iyengar V; Lober C; Margolis D J; Messina J; Miller A; Miller S; Mostow E; Mowad C; Nehal K; Schmitt-Burr K; Sekulic A; Storrs P; Teng J; Yu S; Huang C; Boyer K; Begolka W S; Alam M; Kim J Y S; Kozlow J H; Mittal B; Moyer J; Olencki T; Rodgers P
Journal of the American Academy of Dermatology
2018
2018-03
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1016/j.jaad.2017.10.006" target="_blank" rel="noreferrer noopener">10.1016/j.jaad.2017.10.006</a>
Guidelines Of Care For The Management Of Basal Cell Carcinoma
5-year follow-up; aminolevulinate photodynamic; basal cell carcinoma; biopsy; curettage; Dermatology; expectancy; fresh tissue technique; hedgehog pathway inhibitor; imiquimod 5-percent cream; limited life; metastasis; mohs micrographic surgery; nonmelanoma; open-label trial; phototherapy; radiotherapy; randomized controlled-trial; skin-cancer; staging; Surgery; surveillance; therapy; topical therapy
Bichakjian C; Armstrong A; Baum C; Bordeaux J S; Brown M; Busam K J; Eisen D B; Iyengar V; Lober C; Margolis D J; Messina J; Miller A; Miller S; Mostow E; Mowad C; Nehal K; Schmitt-Burr K; Sekulic A; Storrs P; Teng J; Yu S; Huang C; Boyer K; Begolka W S; Alam M; Kim J Y S; Kozlow J H; Mittal B; Moyer J; Olencki T; Rodgers P
Journal of the American Academy of Dermatology
2018
2018-03
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1016/j.jaad.2017.10.006" target="_blank" rel="noreferrer noopener">10.1016/j.jaad.2017.10.006</a>
Guidelines of care for the management of cutaneous squamous cell carcinoma
5-year follow-up; american joint committee; biopsy; carcinoma; curettage; Dermatology; fresh tissue technique; limited life expectancy; lymph-node biopsy; metastasis; mohs micrographic surgery; nonmelanoma skin-cancer; organ transplant; phototherapy; radiotherapy; randomized controlled-trial; recipients; squamous cell; staging; Surgery; surveillance; topical photodynamic therapy; topical therapy
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of human cancer and has an increasing annual incidence. Although most cSCC is cured with office-based therapy, advanced cSCC poses a significant risk for morbidity, impact on quality of life, and death. This document provides evidence-based recommendations for the management of patients with cSCC. Topics addressed include biopsy techniques and histopathologic assessment, tumor staging, surgical and nonsurgical management, follow-up and prevention of recurrence, and management of advanced disease. The primary focus of these recommendations is on evaluation and management of primary cSCC and localized disease, but where relevant, applicability to recurrent cSCC is noted, as is general information on the management of patients with metastatic disease.
Alam M; Armstrong A; Baum C; Bordeaux J S; Brown M; Busam K J; Eisen D B; Iyengar V; Lober C; Margolis D J; Messina J; Miller A; Miller S; Mostow E; Mowad C; Nehal K; Schmitt-Burr K; Sekulic A; Storrs P; Teng J; Yu S; Huang C; Boyer K; Begolka W S; Bichakjian C; Kim J Y S; Kozlow J H; Mittal B; Moyer J; Olenecki T; Rodgers P
Journal of the American Academy of Dermatology
2018
2018-03
Journal Article or Conference Abstract Publication
<a href="http://doi.org/10.1016/j.jaad.2017.10.007" target="_blank" rel="noreferrer noopener">10.1016/j.jaad.2017.10.007</a>